期刊
SENSORS
卷 21, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/s21020660
关键词
FRET; BRET; CRET; point-of-care; on-site; on-the-spot; microfluidics; PADs; time-resolved FRET
资金
- CSIRO Probing Biosystems Future Science Platform - CSIRO Health & Biosecurity Business Unit
The demand for PON diagnostics is growing, currently serviced by biosensors, with only colorimetric LFIs and electrochemical assays fully meeting the requirements. Other technologies may require modifications to be used in PON settings.
The demand for point-of-need (PON) diagnostics for clinical and other applications is continuing to grow. Much of this demand is currently serviced by biosensors, which combine a bioanalytical sensing element with a transducing device that reports results to the user. Ideally, such devices are easy to use and do not require special skills of the end user. Application-dependent, PON devices may need to be capable of measuring low levels of analytes very rapidly, and it is often helpful if they are also portable. To date, only two transduction modalities, colorimetric lateral flow immunoassays (LFIs) and electrochemical assays, fully meet these requirements and have been widely adopted at the point-of-need. These modalities are either non-quantitative (LFIs) or highly analyte-specific (electrochemical glucose meters), therefore requiring considerable modification if they are to be co-opted for measuring other biomarkers. Forster Resonance Energy Transfer (RET)-based biosensors incorporate a quantitative and highly versatile transduction modality that has been extensively used in biomedical research laboratories. RET-biosensors have not yet been applied at the point-of-need despite its advantages over other established techniques. In this review, we explore and discuss recent developments in the translation of RET-biosensors for PON diagnoses, including their potential benefits and drawbacks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据